Finch Therapeutics Group, Inc. Stock News

Penny stocks to buy according to analysts. The post 4 Penny Stocks To Buy According To Analysts, Targets Up To 1,650% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.c

Finch Therapeutics Group, Inc. (FNCH) delivered earnings and revenue surprises of -12.50% and 90.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead f

Finch Therapeutics Group, Inc. (FNCH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term

SOMERVILLE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging

The FDA, at long last, has lifted a clinical hold on Finch's C. diff program.

Finch Therapeutics (FNCH) stock is rising higher on Friday following news that the FDA has released its clinical hold on CP101. The post Why Is Finch Therapeutics (FNCH) Stock Up 30% Today?

What you need to know about buying penny stocks on April 29th The post Best Penny Stocks to Buy Today? 3 to Watch on April 29th appeared first on Penny Stocks to Buy, Picks, News and Information | Pen

NEW YORK, March 2, 2022 /PRNewswire/ -- PomerantzLLP is investigating claims on behalf of investors of Finch Therapeutics Group, Inc. ("Finch" or the "Company") (NASDAQ: FNCH). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980….

The FDA has issued a clinical hold letter to Finch Therapeutics Group Inc''s (NASDAQ: FNCH ) PRISM4 Phase 3 trial of CP101 in recurrent C. difficile infection (CDI). The Company has paused enrollment in the trial as the FDA has asked for additional information about Finch''s SARS-CoV-2 donor screening protocols. The FDA placed Finch''s investigational new drug application (IND) for CP101 and the IND of its then-contract manufacturer, … Full story available on Benzinga.com

SOMERVILLE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ: FNCH ), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel class of orally administered biological drugs, today announced that the U.S. Patent and Trademark Office has issued two new patents covering the company''s FIN-211 enriched consortia microbiome product candidate in development for children with autism spectrum disorder (ASD) and significant gastrointestinal (GI) symptoms. The company''s intellectual property portfolio now includes 59 issued U.S. and foreign patents with more than 130 patent applications pending. The first patent (U.S. Patent No. 11,202,808) covers key technologies involved in addressing ASD and GI symptoms associated with ASD by orally administering a donor-derived microbial community enriched with bacterial isolates from a genus with potential therapeutic applications in ASD.

Finch Therapeutics Group Inc (FNCH) shares closed today 15.8% higher than it did at the end of yesterday. The stock is currently down 49.4% year-to-date, down 49.4% over the past 12 months, and down 49.4% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $11.16 and as low as $8.77 this week.Shares closed 52.0% below its 52-week high and 23.0% above its 52-week low.Trading volume this week was 75.3% lower than the 10-day average and 72.3% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Finch Therapeutics Group Inc (FNCH) shares closed today 15.8% higher than it did at the end of yesterday. The stock is currently down 49.4% year-to-date, down 49.4% over the past 12 months, and down 49.4% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $11.16 and as low as $8.77 this week.Shares closed 52.0% below its 52-week high and 23.0% above its 52-week low.Trading volume this week was 77.2% lower than the 10-day average and 71.9% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Finch Therapeutics Group, Inc. (NASDAQ:FNCH) Director Nicholas Haft purchased 63,850 shares of the business’s stock in a transaction on Monday, December 20th. The shares were acquired at an average price of $10.18 per share, for a total transaction of $649,993.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which […]